期刊文献+

肝功能不全患者的临床用药 被引量:5

下载PDF
导出
摘要 在临床疾病的治疗过程中,患者有时不仅患有某种药物所治疗的疾病,还常常同时伴有肝脏疾病,肝功能不良。肝脏器质性病变会造成患者机体内环境和各系统脏器功能失调,一方面会使机体对药物的吸收、分布、代谢、排泄等发生变化,导致药动学改变;另一方面会使某些组织器官的受体数目和功能发生变化,改变机体对相应药物的反应性,导致药效学改变。对这类患者的用药应当引起重视。
作者 阮耀
出处 《中国现代药物应用》 2009年第15期136-137,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献3

二级参考文献8

  • 1Servin F, Cockshott I D, Farinotti R, et al. Pharmacokinetics of propofol infusions in patients with cirrhosis[J]. Br J Anaesth, 1990, 65(2) : 177 -183.
  • 22000 Annual Report of the Scientific Registry of transplant recipients and the organ procurement and transplantation network : transplant data 1989-1998. Richmond, VA: United Network of Organ Sharing, 2001 - 2002.
  • 3Mazoit J X, Samii K. Binding of propofol to blood components : implications for pharmacokinetics and for pharmacodynamics [ J ]. Br J Clin Pharmacol, 1999, 47( 1 ) : 35 -42.
  • 4Servin F, Desmonts J M, Haberer J P, et al. Pharmacokinetics and protein binding of propofol in patients with cirrhosis[ J]. Anesthesiology, 1988, 69(6) : 887 -891.
  • 5Zamacona M K, Suarez E, Garcia E, et al. The significance of lipoproteins in serum binding variations of propofol [ J ]. Anesth Analg, 1998, 87(5) : 1147 - 1151.
  • 6Raoof A A, van-Obbergh L J, de-Ville-de-Goyet J, et al. Extrahepatic glucuronidation of propofol in man: possible contribution of gut wall and kidney[J]. Eur J Clin Pharmacol, 1996, 50( 1 -2) : 91 -96.
  • 7Takizawa D, Hiraoka H, Goto F, et al. Human kidneys play an important role in the elimination of propofol [ J ]. Anesthesiology, 2005, 102 (2) : 327 - 330.
  • 8Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study [ J]. Anesthesiology, 2000, 92(3): 727- 738.

共引文献14

同被引文献35

  • 1郑章强,朱志军.肝脏低温机械灌注保存的研究进展[J].实用器官移植电子杂志,2013,1(2):120-123. 被引量:12
  • 2申强.指导患者合理用药 提高用药依从性[J].现代医院,2012,12(S1):60-61. 被引量:5
  • 3罗继名,徐萍.肝功能不全患者抗菌药物的选择[J].中南药学,2006,4(1):73-74. 被引量:11
  • 4黄世杰.肝硬化病人的用药剂量调整[J].国外医学(药学分册),2006,33(2):120-122. 被引量:4
  • 5王自法,朱晓丹,臧运金,沈中阳.临床肝移植的适应症与手术时机[J].医学信息(手术学分册),2006,19(4):3-5. 被引量:2
  • 6BERENGUER B, LA CASA C, DE LA MATrA M J, et al. Phar- maceutical care : past, present and future [ J ]. Cttrr Pharm Des, 2004,10(31 ) :3931 -3946.
  • 7HEPLER C D, STRAND L M. Opportunities and responsibilities in pharmaceutical care [ J ]. Am J Hosp Pharm, 1990,47 ( 3 ) : 533 - 543.
  • 8FDA, CDER, CBER. Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function:Study Design, Data Anal- ysis, and Impact on Dosing and Labeling [ EB/OL]. http : ff www. fda. gov/eber/guidelines, htm ,2003 - 5/2011 - 3.
  • 9EMA. Guideline on the evaluation of the phamaeokinetics of medi- cine products in impairment hepatic function [ EB/OL]. http:// www. ema. europa, eu/pdfs/human/ewp/233902en, pdf, 2005 - 2 - 17/2011 - 3.
  • 10Warrington S,Bailey K,Boyce M,et al.Effects of rabeprazole,20mg,or esomeprazole,20mg,on 24hintragastric pH and serum gastrin in healthy subjects[J].Aliment Pharmacol Ther,2002,16:1301-1307.

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部